Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.
Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs.
Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
Addex's lead drug candidate, dipraglurant (mGlu5 NAM), has successfully completed a Phase 2a POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID. In parallel, dipraglurant's therapeutic use in dystonia is being investigated in preclinical models.
Addex's second clinical program, ADX71149 (mGlu2 PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for the treatment of epilepsy.
Preclinical programs include:
Addex was founded in 2002, headquartered in Geneva, Switzerland and listed on the SIX Swiss Stock Exchange under the trading symbol ADXN since 2007.
Find out more about our Clinical and Pre-Clinical Pipeline.